1. Home
  2. TRIB

TRIB

Trinity Biotech plc

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-24-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.

Founded: 1992 Country:
Ireland
Ireland
Employees: N/A City: N/A
Market Cap: 14.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 98.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.96 EPS Growth: N/A
52 Week Low/High: $1.81 - $6.20 Next Earning Date: 04-04-2024
Revenue: $56,832,000 Revenue Growth: -9.10%
Revenue Growth (this year): 20.25% Revenue Growth (next year): 9.70%

Share on Social Networks: